Immunic AG | WebDisclosure

BRIEF

published on 05/08/2024 at 12:35, 6 months 13 days ago

Immunic, Inc. Announces Q1 2024 Financial Results and Corporate Updates

Financial Strategy Immunic Inc Q1 2024 Financial Report Multiple Sclerosis Trials Celiac Disease Treatment
PRESS RELEASE

published on 05/08/2024 at 12:30, 6 months 13 days ago

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
Immunic, Inc. reports first quarter 2024 financial results, including capital increase and progress in MS and gastrointestinal disease therapies

Financial Results Clinical Trials Immunic Inc. Gastrointestinal Disease MS Therapy
BRIEF

published on 05/06/2024 at 12:35, 6 months 15 days ago

Immunic AG annonce sa participation aux conférences de mai destinées aux communautés d'investisseurs et scientifiques

Essais Cliniques Conférences Investisseurs Immunic SA Conférences Scientifiques Traitements Des Maladies Auto-immunes
BRIEF

published on 05/06/2024 at 12:35, 6 months 15 days ago

Immunic AG Announces Participation in May Conferences for Investor and Scientific Communities

Investor Conferences Clinical Trials Immunic AG Scientific Conferences Autoimmune Disease Treatments
PRESS RELEASE

published on 05/06/2024 at 12:30, 6 months 15 days ago

Immunic to Participate in Investor and Scientific Conferences in May
Immunic, Inc. to participate in investor and scientific conferences in May, presenting clinical trial data on oral therapies for inflammatory diseases

Investor Conferences Clinical Trials Immunic Inc. Inflammatory Diseases Scientific Conferences
BRIEF

published on 04/30/2024 at 12:35, 6 months 21 days ago

Immunic présente des données étendues de l'essai EMPhASIS dans une revue à comité de lecture

Vidofludimus Calcium Neuroprotection Essai EMPhASIS Sclérose En Plaques Rémittente Modulation Immunitaire
BRIEF

published on 04/30/2024 at 12:35, 6 months 21 days ago

Immunic Highlights Extended Data from EMPhASIS Trial in Peer-Reviewed Journal

Vidofludimus Calcium EMPhASIS Trial Relapsing-remitting Multiple Sclerosis Neuroprotection Immune Modulation
PRESS RELEASE

published on 04/30/2024 at 12:30, 6 months 21 days ago

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in RRMS in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation
Immunic announces publication of extended data from phase 2 EMPhASIS trial of Vidofludimus Calcium in RRMS in Neurology Neuroimmunology & Neuroinflammation journal

Immunic Vidofludimus Calcium EMPhASIS Trial Neurology Journal RRMS
BRIEF

published on 04/04/2024 at 12:35, 7 months 17 days ago

Immunic participera à la prochaine journée de recherche sur la SEP et aux conférences pour les investisseurs

Biotechnologie Vidofludimus Calcium Conférences Investisseurs Immunitaire Recherche Sur La SP
BRIEF

published on 04/04/2024 at 12:35, 7 months 17 days ago

Immunic to Participate in Upcoming MS Research Day and Investor Conferences

Biotechnology Investor Conferences Immunic Vidofludimus Calcium MS Research

Published on 11/21/2024 at 16:01, 20 minutes ago

Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Published on 11/21/2024 at 16:00, 21 minutes ago

Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight
Published on 11/21/2024 at 16:00, 21 minutes ago

Wiz Acquires Dazz to Revolutionize Cloud Security Remediation
Published on 11/21/2024 at 16:00, 21 minutes ago

Isaac Ullatil Joins Wellstack Board of Directors
Published on 11/21/2024 at 15:30, 51 minutes ago

CLS Health Opens New Comprehensive Care Clinic in Sugar Creek

View all ACCESSWIRE

Published on 11/21/2024 at 16:00, 21 minutes ago

Director/PDMR Shareholding
Published on 11/21/2024 at 15:41, 39 minutes ago

Edison issues report on Murray Income Trust (MUT)
Published on 11/21/2024 at 15:24, 57 minutes ago

Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/21/2024 at 15:23, 58 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Centamin plc
Published on 11/21/2024 at 15:22, 59 minutes ago

Form 8.3 - The Vanguard Group, Inc.: TI Fluid Systems plc

View all EQS

Published on 11/21/2024 at 06:58, 9 hours 23 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 9 hours 23 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 9 hours 23 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 20 hours 14 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 21 hours 1 minute ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE

News